

Special Issue

Tumor-Associated Microenvironments and Inflammation

Message from the Guest Editors

The tumor microenvironment (TME) is the complex non-cancerous cellular and non-cellular compartments presented in and around the tumor, including fibroblasts, immune cells, adipocytes, and cells that comprise the blood vessels. It has been shown that cancer cell plasticity and stemness are modulated by biochemical and biophysical cues derived from the TME, which in turn promotes cancer metastasis and therapeutic resistance. Cancer cells also produce a variety of growth factors and chemokines to modulate the function of these cells. Targeting the TME has proven to be a promising strategy for cancer therapy. Angiogenesis inhibitors have been approved by the FDA for the treatment of solid tumors. Therefore, further elucidating the molecular and cellular biology of TME in cancer development and progression is critical for us to eventually eliminate cancer-related death. This Special Issue will highlight the current state of the art in the function and regulation of cancer-associated fibroblasts, adipocytes, immune cells, ECM remodeling, and prospects for improving TME-related therapies.

Guest Editors

Prof. Dr. Ren Xu

Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA

Dr. Bing Li

Department of Microbiology and Immunology, School of Medicine, University of Louisville, Louisville, KY 40536, USA

Deadline for manuscript submissions

closed (5 November 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/137459

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)